Hemab Therapeutics Holdings, Inc. COAG Stock Forecast
AI-powered price prediction and analysis for Hemab Therapeutics Holdings, Inc. · Total · absolute moveSwitch to Alpha
See COAG's Exact Price Target · Create a free account and follow this stock to unlock its full AI forecast — 3 stocks free.
Price Chart
Key Statistics
About Hemab Therapeutics Holdings, Inc.
Hemab Therapeutics Holdings, Inc. (COAG) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry.
Latest News
Where COAG sits on the market map
Biological Products, (No Diagnostic Substances) Peers
Companies sharing the same SEC industry code, one row per issuer, largest first - a classification match, not a curated list of competitors.
| Company | AI Signal | Market Cap | P/E |
|---|---|---|---|
| COAG Hemab Therapeutics Holdings, Inc. | ▶ | $1.50B | – |
| AMGN Amgen Inc | ▼ | $229.74B | 26.4x |
| GILD Gilead Sciences, Inc. | ▶ | $189.80B | – |
| MRNA Moderna, Inc. | ▲ | $90.58B | – |
| ARGX Argenx Se | ▼ | $51.09B | 21.7x |
| RVMD Revolution Medicines, Inc. | ▲ | $39.04B | – |
| BIIB Biogen Inc. | ▼ | $34.25B | 25.1x |
| BNTX Biontech Se | ▲ | $22.56B | 2.3x |
| EXEL Exelixis, Inc. | ▼ | $15.53B | 18.1x |
| NBIX Neurocrine Biosciences Inc | ▲ | $13.92B | 19.8x |
| HALO Halozyme Therapeutics, Inc. | ▶ | $13.90B | 28.2x |
| TECH Bio-Techne Corp | ▼ | $11.37B | 62.5x |
| QGEN Qiagen N.V. | ▶ | $10.10B | 33.0x |
| RGEN Repligen Corp | ▲ | $9.96B | 255.7x |
| KRYS Krystal Biotech, Inc. | ▶ | $9.48B | 40.2x |
| PCVX Vaxcyte, Inc. | ▲ | $9.48B | – |
| KYMR Kymera Therapeutics, Inc. | ▲ | $8.99B | – |
| IBRX Immunitybio, Inc. | ▲ | $8.92B | – |
| TWST Twist Bioscience Corp | ▲ | $8.76B | – |
| IOVA Iovance Biotherapeutics, Inc. | ▲ | $6.44B | – |
| KOD Kodiak Sciences Inc. | ▲ | $5.74B | – |
| IMVT Immunovant, Inc. | ▲ | $5.70B | – |
| CGON Cg Oncology, Inc. | ▲ | $5.31B | – |
| SRRK Scholar Rock Holding Corp | ▲ | $4.90B | – |
| CRSP Crispr Therapeutics Ag | ▲ | $4.84B | – |
| ADPT Adaptive Biotechnologies Corp | ▲ | $3.90B | – |
| RLAY Relay Therapeutics, Inc. | ▲ | $3.75B | – |
| TARS Tarsus Pharmaceuticals, Inc. | ▶ | $3.05B | – |
| DNLI Denali Therapeutics Inc. | ▶ | $2.88B | – |
| ADMA Adma Biologics, Inc. | ▼ | $2.52B | 18.1x |
| BEAM Beam Therapeutics Inc. | ▲ | $2.50B | 96.8x |
| LIFE Atyr Pharma Inc | ▲ | $2.48B | – |
| RXRX Recursion Pharmaceuticals, Inc. | ▲ | $2.16B | – |
| VCEL Vericel Corp | ▶ | $2.07B | 109.1x |
| BCRX Biocryst Pharmaceuticals Inc | ▲ | $2.06B | – |
| ALVO Alvotech | ▲ | $1.80B | – |
| NVAX Novavax Inc | ▲ | $1.78B | – |
| VIR Vir Biotechnology, Inc. | ▲ | $1.73B | – |
| MAZE Maze Therapeutics, Inc. | ▲ | $1.65B | – |
| MESO Mesoblast Ltd | ▶ | $1.55B | – |
| IMCR Immunocore Holdings Plc | ▼ | $1.54B | – |
| TSHA Taysha Gene Therapies, Inc. | ▲ | $1.28B | – |
| VOR Vor Biopharma Inc. | ▲ | $1.07B | – |
| REPL Replimune Group, Inc. | ▲ | $1.04B | – |
| JATT Zura Bio Ltd | ▶ | $994M | – |
| IMTX Immatics N.V. | ▲ | $945M | – |
| GLUE Monte Rosa Therapeutics, Inc. | ▲ | $909M | – |
| MGTX Meiragtx Holdings Plc | ▶ | $908M | 12.3x |
| CGEM Cullinan Therapeutics, Inc. | ▲ | $900M | – |
| SLBT Sl Science Holding Ltd | ▶ | $873M | – |
| ODTX Odyssey Therapeutics, Inc. | ▶ | $870M | – |
| PRME Prime Medicine, Inc. | ▲ | $695M | – |
| SANA Sana Biotechnology, Inc. | ▲ | $689M | – |
| FDMT 4d Molecular Therapeutics, Inc. | ▲ | $679M | – |
| DNA Ginkgo Bioworks Holdings, Inc. | ▲ | $678M | – |
| AURA Aura Biosciences, Inc. | ▲ | $652M | – |
| SLDB Solid Biosciences Inc. | ▲ | $635M | – |
| CADL Candel Therapeutics, Inc. | ▲ | $628M | – |
| DBVT Dbv Technologies S.A. | ▼ | $531M | – |
| VALN Valneva Se | ▼ | $521M | – |
FAQ
Is Hemab Therapeutics Holdings, Inc. a good stock to buy?
Our AI analyzes Hemab Therapeutics Holdings, Inc. daily. Check the signal above for the latest recommendation. Always do your own research before investing.
How accurate are Hemab Therapeutics Holdings, Inc. predictions?
For COAG, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 53.0%, measured on 44 forecast dates between 2026-05-21 and 2026-07-21 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -32.0%, measured on 87 forecast dates between 2026-05-21 and 2026-09-18. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are forecasts updated?
Hemab Therapeutics Holdings, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 19, 2026.
Ready to invest smarter? · Join thousands of investors using AI-powered stock predictions
Sign Up FreeLooking for a deeper analysis of Hemab Therapeutics Holdings, Inc.? View full institutional-grade analysis on Intratio →
AI predictions are based on historical patterns and should not be the sole basis for investment decisions. Past performance does not guarantee future results. Always do your own research.